Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting an...

Industry: Biotechnology
Sector: Healthcare
Phone: 416-964-5442
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Itsybitsybeanbag
Itsybitsybeanbag Sep. 19 at 1:35 PM
$MDNAF It seems that I’ve wished away the last 3 years waiting for data… man Biotech makes you old quick!!!
2 · Reply
bobwut12
bobwut12 Sep. 18 at 9:36 PM
$MDNAF Anybody have any idea why out of the whopping 254 companies that RA Capital's website lists in their Portfolio, there isn't any mention of Medicenna at all? https://www.racap.com/portfolio
3 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Sep. 18 at 5:29 PM
$MDNAF less than two months… that’s one positive!
1 · Reply
Lytnup
Lytnup Sep. 17 at 4:09 PM
$MDNAF Link to webcast & slide deck https://ir.medicenna.com/events/event-details/hc-wainwright-28th-annual-global-investment-conference I may have missed it - any ideas on which conference(s) they will be presenting at?
1 · Reply
DIJG
DIJG Sep. 17 at 2:21 PM
$MDNAF As of 10AM to day. So much for the stock market... lol Market maker doing their thing. 167 shares less than 70$ can bring down the price whereas 4000 shares $1600 couldnt bump it
0 · Reply
DIJG
DIJG Sep. 16 at 5:48 PM
$MDNAF Major Takeaway From Today’s Investor Conference Ability 1 has now expanded to 150 patients, a meaningful scale up from the original 80, then 115, and now 150 across multiple solid tumor types. The upcoming data will concentrate on four key cohorts: Melanoma,Endometrial cancer,GI tumors,TMB high These represent high value indications where PD 1 therapies often underperform — making MDNA11’s differentiated IL 2 biology particularly relevant. External Scientific Validation Strengthens the Thesis A Science Advances publication released ~10 days ago by the BioNTech co founder (developer of the recently sucessful cancer vaccine) provides an important independent validation point: Beta enhanced IL 2 variants significantly improve anti tumor efficacy. This directly reinforces Medicenna’s engineering strategy, because MDNA11 is a beta enhanced IL 2 superkine designed precisely to exploit this mechanism.
4 · Reply
DIJG
DIJG Sep. 14 at 1:54 PM
$MDNAF ABILITY‑1 began on 14 September 2021, making the program five years old today — a really long journey for investors. After multiple high‑profile IL‑2 failures, no pharma wanted to touch another IL‑2, and the first news release shows it clearly: no checkpoint partner listed (screenshot). MDNA11 had to prove itself from zero. Then 1 data after another: 22 December 2021: 1st safety and PK results landed. 22 May 2022: Dose‑dependent immune activation showing 10‑fold and 17‑fold increases in NK and CD8 T cells at only one‑third of the projected dose. 27 July 2022: First efficacy signal landed showing anti‑tumor activity in a setting where KEYTRUDA had failed. Only after seeing this sequence did Merck step in with a collaboration agreement+JDC on 13SEP2022 roughly 1month after 1st efficacy readout. MDNA11 continued to generate strong monotherapy efficacy for another 1year.
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Sep. 11 at 6:45 PM
$MDNAF A few months ago he posted that Medicenna was at ASCO and BIO and invited people to meet to hear about MDNA11, MDNA113 and bizaxofusp. And on September 9–10—literally this week—he participated in Boston’s Oncology & Immunology Innovation Partnering & Licensing Summit, whose stated purpose is to put pharma BD/search-and-evaluation people together with biotechs for licensing and co-development discussions. Attending companies included Merck, Lilly, J&J, Takeda, Novartis and other
2 · Reply
DIJG
DIJG Sep. 11 at 11:33 AM
$MDNAF Medicenna quietly added a Chief Business Advisor, John Mayfield, PhD — no press release, but he’s on their website and his LinkedIn shows he joined a 3-4 months ago. His LindkIn suggests he contributed to securing a deal with Merck at his previous. A CBA is a strategic hire used when a biotech is entering a critical phase where it needs to turn clinical progress into business outcome. It may also signal Medicenna is opening the door to options beyond Merck & possibly a bidding war with CBA managing inbound interests.
1 · Reply
DIJG
DIJG Sep. 10 at 2:53 PM
$MDNAF Learn more about Merck dealmaking: https://www.merck.com/stories/new-podcast-meet-the-dealmakers/ full podcast at bottom of page.Sometimes a coy is looking to exit i.e. be acquired or they want to build on themself and just want a flagship company like us to guide them.Neuroscince & Immuno-oncology being one of Mercks 5 pillars, Medicenna has two strong platforms to offer if data continues to be good MDNA55 & MDNA11/113
0 · Reply
Latest News on MDNAF
No data available.
Itsybitsybeanbag
Itsybitsybeanbag Sep. 19 at 1:35 PM
$MDNAF It seems that I’ve wished away the last 3 years waiting for data… man Biotech makes you old quick!!!
2 · Reply
bobwut12
bobwut12 Sep. 18 at 9:36 PM
$MDNAF Anybody have any idea why out of the whopping 254 companies that RA Capital's website lists in their Portfolio, there isn't any mention of Medicenna at all? https://www.racap.com/portfolio
3 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Sep. 18 at 5:29 PM
$MDNAF less than two months… that’s one positive!
1 · Reply
Lytnup
Lytnup Sep. 17 at 4:09 PM
$MDNAF Link to webcast & slide deck https://ir.medicenna.com/events/event-details/hc-wainwright-28th-annual-global-investment-conference I may have missed it - any ideas on which conference(s) they will be presenting at?
1 · Reply
DIJG
DIJG Sep. 17 at 2:21 PM
$MDNAF As of 10AM to day. So much for the stock market... lol Market maker doing their thing. 167 shares less than 70$ can bring down the price whereas 4000 shares $1600 couldnt bump it
0 · Reply
DIJG
DIJG Sep. 16 at 5:48 PM
$MDNAF Major Takeaway From Today’s Investor Conference Ability 1 has now expanded to 150 patients, a meaningful scale up from the original 80, then 115, and now 150 across multiple solid tumor types. The upcoming data will concentrate on four key cohorts: Melanoma,Endometrial cancer,GI tumors,TMB high These represent high value indications where PD 1 therapies often underperform — making MDNA11’s differentiated IL 2 biology particularly relevant. External Scientific Validation Strengthens the Thesis A Science Advances publication released ~10 days ago by the BioNTech co founder (developer of the recently sucessful cancer vaccine) provides an important independent validation point: Beta enhanced IL 2 variants significantly improve anti tumor efficacy. This directly reinforces Medicenna’s engineering strategy, because MDNA11 is a beta enhanced IL 2 superkine designed precisely to exploit this mechanism.
4 · Reply
DIJG
DIJG Sep. 14 at 1:54 PM
$MDNAF ABILITY‑1 began on 14 September 2021, making the program five years old today — a really long journey for investors. After multiple high‑profile IL‑2 failures, no pharma wanted to touch another IL‑2, and the first news release shows it clearly: no checkpoint partner listed (screenshot). MDNA11 had to prove itself from zero. Then 1 data after another: 22 December 2021: 1st safety and PK results landed. 22 May 2022: Dose‑dependent immune activation showing 10‑fold and 17‑fold increases in NK and CD8 T cells at only one‑third of the projected dose. 27 July 2022: First efficacy signal landed showing anti‑tumor activity in a setting where KEYTRUDA had failed. Only after seeing this sequence did Merck step in with a collaboration agreement+JDC on 13SEP2022 roughly 1month after 1st efficacy readout. MDNA11 continued to generate strong monotherapy efficacy for another 1year.
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Sep. 11 at 6:45 PM
$MDNAF A few months ago he posted that Medicenna was at ASCO and BIO and invited people to meet to hear about MDNA11, MDNA113 and bizaxofusp. And on September 9–10—literally this week—he participated in Boston’s Oncology & Immunology Innovation Partnering & Licensing Summit, whose stated purpose is to put pharma BD/search-and-evaluation people together with biotechs for licensing and co-development discussions. Attending companies included Merck, Lilly, J&J, Takeda, Novartis and other
2 · Reply
DIJG
DIJG Sep. 11 at 11:33 AM
$MDNAF Medicenna quietly added a Chief Business Advisor, John Mayfield, PhD — no press release, but he’s on their website and his LinkedIn shows he joined a 3-4 months ago. His LindkIn suggests he contributed to securing a deal with Merck at his previous. A CBA is a strategic hire used when a biotech is entering a critical phase where it needs to turn clinical progress into business outcome. It may also signal Medicenna is opening the door to options beyond Merck & possibly a bidding war with CBA managing inbound interests.
1 · Reply
DIJG
DIJG Sep. 10 at 2:53 PM
$MDNAF Learn more about Merck dealmaking: https://www.merck.com/stories/new-podcast-meet-the-dealmakers/ full podcast at bottom of page.Sometimes a coy is looking to exit i.e. be acquired or they want to build on themself and just want a flagship company like us to guide them.Neuroscince & Immuno-oncology being one of Mercks 5 pillars, Medicenna has two strong platforms to offer if data continues to be good MDNA55 & MDNA11/113
0 · Reply
DIJG
DIJG Sep. 7 at 4:44 PM
$MDNAF Be on the lookout for your VIF — I received mine last week. The reverse‑split question is included but it appears as “share consolidation".
1 · Reply
DIJG
DIJG Sep. 3 at 1:21 PM
$MDNAF Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference September 16 https://ir.medicenna.com/news-releases/news-release-details/medicenna-present-hc-wainwright-28th-annual-global-investment
1 · Reply
DIJG
DIJG Sep. 3 at 12:47 PM
$MDNAF The schedules for the major upcoming conferences are out, even though company names and oral abstracts remain hidden. https://www.sitcancer.org/2026/schedule/sitc-2026-schedule https://www.esmo.org/meeting-calendar/esmo-congress-2026/programme If “major conference” in the 2026 news release wasn’t just casual wording, then we’re talking about the small group of truly major oncology meetings — and the December ESMO IO Congress isn’t one of them. It’s respected, but not a global flagship like the main ESMO Congress in October, and Medicenna correctly didn’t label it as major. 2026 & 2025 screenshots below for reference No red flag here: companies submit wherever the data maturity fits. The simple takeaway is that if we stick to major conferences, both updates should arrive before December.Based on Mechanistic fit & precedent, My guess would be MDNA55 → ESMO Congress (October 2026) MDNA11 → SITC (November 2026)
0 · Reply
bobwut12
bobwut12 Sep. 3 at 7:44 AM
$MDNAF Anyone familiar with Briacell ($BCTX) will know that reverse splits are pain incarnate. It didn't matter at all that they had great science with heaps of great data and multiple oral presentations at prestigious conferences over the years - the reverse splits have made it so that literally all of the OG investors have essentially lost everything (I tried amazing down over the course of like 2 years but am still down ~97% total lol). Management that promote reverse splits are not management to be trusted. I personally thought it was great back then when Dr. Merchant decided to delist from the NASDAQ to OTC instead of doing a reverse split - I have no idea where this new proposal is coming from or why (price purchasing thresholds for firms don't matter for OTC stocks).
4 · Reply
ewll
ewll Sep. 3 at 3:08 AM
$MDNAF Use your rights to vote against R/S if you don't like the idea.
0 · Reply
Pilotboy1985
Pilotboy1985 Sep. 3 at 12:24 AM
$MDNAF Getting heat for saying an R/S isn't automatically a death sentence, but look at how structural resets actually play out in biotech: 1) Enabling Authority vs. Action: Management got this exact approval in 2023 and let it expire. It’s back-pocket insurance, not a done deal. 2)The Compliance Hurdle: Sub-dollar prices block institutional capital and partnerships. Clearing that threshold is often a required administrative box. 3)The Data Reality: Plenty of biotechs utilized structural cleanups during micro-cap phases before pipeline catalysts drove their long-term value (e.g., historical success stories like Arrowhead [ARWR], or Assembly Biosciences [ASMB] which saw multi-month post-split recoveries exceeding +30% once operational momentum kicked in). Not cheering for it, but treating it like a guaranteed killer ignores how pre-revenue biotech works. Data matters most. IMO!
1 · Reply
DIJG
DIJG Sep. 2 at 1:57 PM
$MDNAF Advice for management: the priority right now should be the upcoming data readouts. That’s where all the real value sits. Bring in a strong PR firm that knows how to amplify biotech catalysts — one that can shape the narrative, push the news into the right channels, and line up targeted interviews to reinforce the impact of the results. Discussing a potential R/S is nothing but a distraction. It doesn’t move the science, it doesn’t move the data. The focus should be on execution, communication, and making sure the data gets the visibility it deserves. If the impact of the comming readout is fully maximized, a R/S should not even be necessary.
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Sep. 2 at 12:44 PM
$MDNAF R/S are NEVER good… period. It’s desperation
0 · Reply
_Osmium
_Osmium Sep. 2 at 12:24 PM
$MDNAF Although one poster put a positive slant to a potential reverse split, the reality is almost never good. A simple Ai query of that strategy will give you a less than positive assessment. Shareholders hope this doesn't materialize and I agree with another poster that a "no" vote is warranted. Positive NEO-CYT data would likely back pocket the reverse split and maybe even encourage a partner to step forward? Then we wait until December ESMO for the ABILITY study readout. It's obvious these next few months are the fate of the company. Nerve racking to say the least. All imo
0 · Reply
DIJG
DIJG Sep. 1 at 9:04 PM
$MDNAF NEW Filing: Potential reverse split will be up for discussion at the AGM.The CEO once rejected this idea- i'm just wondering why the need now? Of course it comes with several advantages to re-list to NASDAQ: Analyst coverage, improved Acquisition mechnics and perceived optics on acquirer, institutional visibility etc My personal opinion is that with strong data, the price can organically rise above the minimum bid price required for relisting to NASDAQ. Management need some convincing to do and i will require more info than we want to do it to regain NASDAQ compliance otherwise, if this is put to a vote, i will vote NO
3 · Reply
DIJG
DIJG Aug. 31 at 5:45 PM
$MDNAF For anyone who thinks MDNA11’s patient size is “too small,” historical precedent shows the opposite. e.g Terns (TERN‑701) – 55–63 patients Merck paid $6.7B. Harpoon (HPN328) – ~70–80 treated Merck acquired the entire company. Prometheus –~120 patients $10.8B acquisition. VelosBio – ~50 patients Acquired by Amgen. IL‑2 space (where MDNA11 competes) Synthorx (THOR‑707) – 20–30 patients Acquired for $2.5B. Nektar (NKTR‑214) – 40–50 patients BMS partnership worth $1.85B. Xilio (XTX202) – 20–30 patients Partnered with Gilead. Across IL‑2 deals, no program exceeded 50 patients at the time of acquisition/partnership. ABILITY‑1: 115 patients planned+ NEO‑CYT: 80 patients planned ,total of 195 ptients ABILITY‑1 enrollment completes inQ3. By Q4, assuming: ~80 evaluable patients from ABILITY‑1 and assuming very slow enrolment for Neo-cyt ~7 evaluable patients from NEO‑CYT MDNA11 would have ~87 evaluable patients. This is 2–3× larger than the patient size behind others.
1 · Reply
DIJG
DIJG Aug. 28 at 4:58 PM
$MDNAF MDNA’s tape tells the story: those repeated 500‑share prints aren’t humans, they’re algorithms doing what they do best. A tiny 500‑share sell can drag the price down, yet a 9,000‑share buy barely moves it — classic microcap order‑book imbalance. Fortunately, the science isn’t nearly as unstable as the stock price. One day, the price will have no choice but to catch up to the data.
0 · Reply